Florida Attorney General sues Pfizer and CEO over COVID-19 vaccine claims

•24d ago

Florida Attorney General sues Pfizer and CEO over COVID-19 vaccine claims

Tap title to read story

0:00 / 0:41

Florida Attorney General James Uthmeier filed a lawsuit in state court against Pfizer and its Chief Executive Officer Albert Bourla, accusing the pharmaceutical giant of misleading consumers regarding the safety, effectiveness, and market conduct of its COVID-19 vaccine. The lawsuit alleges that Pfizer falsely marketed the vaccine as safe while omitting potential risks such as heart inflammation and other adverse effects, and that it promoted the vaccine for stopping transmission without prior testing for transmission prevention. Furthermore, the state claims Pfizer used unfair tactics to dominate the market, earning over eighty billion dollars from vaccine sales while quadrupling prices in 2023. Pfizer responded by stating its representations have been accurate and science-based, standing firmly behind the safety and efficacy of its vaccine.

Published 2026-10-01 22:50:45 UTC · Published by JQJO

Prepared by Yusra M. · AI assisted

More context

Timeline

On December 11, 2020, FDA issued emergency use authorization for Pfizer-BioNTech COVID-19 vaccine.
On August 23, 2021, FDA granted full approval for the Pfizer-BioNTech COVID-19 vaccine for individuals sixteen and older.
On January 1, 2023, Pfizer increased vaccine prices to a range of one hundred ten to one hundred thirty dollars per dose.
On December 13, 2023, Florida Supreme Court approved a statewide grand jury request to investigate COVID-19 vaccines.
On February 15, 2024, Florida Surgeon General issued guidance advising against mRNA COVID-19 vaccines for certain groups.
On September 15, 2026, State legal teams finalized the consumer protection complaint against Pfizer and its executives.
On October 1, 2026, Florida Attorney General James Uthmeier officially filed the lawsuit against Pfizer and CEO Albert Bourla.
On October 1, 2026, Media outlets widely reported the state court filing, detailing consumer protection and price allegations.
On October 1, 2026, Financial markets observed minor drops in Pfizer shares following the public announcement of the litigation.
On October 2, 2026, Pfizer defended its vaccine safety records, asserting that its statements were science-based and accurate.

Why it matters

Immediate US impact: Legal scrutiny and public debate intensify surrounding pharmaceutical marketing practices and COVID-19 vaccine safety claims. Possible long-term US impact: Could set precedent for state-level consumer protection lawsuits against vaccine manufacturers and pharmaceutical pricing strategies. Most affected groups: Pfizer executives, Florida healthcare consumers, legal analysts, and federal health regulatory agencies. Reader Prioritization: Prioritise official court filings, statements from the Florida Attorney General, and official responses from Pfizer.

Coverage notes

Left: Focuses on public health protection, scientific consensus, and critiques of state-level challenges to federal vaccination efforts. Center: Emphasizes the legal details of the consumer protection lawsuit, financial impacts on Pfizer shares, and corporate responses. Right: Highlights accountability for pharmaceutical corporations, pricing transparency, and the scrutiny of vaccine marketing practices.